Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: A report from the LEAP Consortium Journal Article
| Authors: | Pikman, Y.; Tasian, S. K.; Sulis, M. L.; Stevenson, K.; Blonquist, T. M.; Apsel Winger, B.; Cooper, T. M.; Pauly, M.; Maloney, K. W.; Burke, M. J.; Brown, P. A.; Gossai, N.; McNeer, J. L.; Shukla, N. N.; Cole, P. D.; Kahn, J. M.; Chen, J.; Barth, M. J.; Magee, J. A.; Gennarini, L.; Adhav, A. A.; Clinton, C. M.; Ocasio-Martinez, N.; Gotti, G.; Li, Y.; Lin, S.; Imamovic, A.; Tognon, C. E.; Patel, T.; Faust, H. L.; Contreras, C. F.; Cremer, A.; Cortopassi, W. A.; Garrido Ruiz, D.; Jacobson, M. P.; Dharia, N. V.; Su, A.; Robichaud, A. L.; Saur Conway, A.; Tarlock, K.; Stieglitz, E.; Place, A. E.; Puissant, A.; Hunger, S. P.; Kim, A. S.; Lindeman, N. I.; Gore, L.; Janeway, K. A.; Silverman, L. B.; Tyner, J. W.; Harris, M. H.; Loh, M. L.; Stegmaier, K. |
| Article Title: | Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: A report from the LEAP Consortium |
| Abstract: | Despite a remarkable increase in the genomic profiling of cancer, integration of genomic discoveries into clinical care has lagged behind. We report the feasibility of rapid identification of targetable mutations in 153 pediatric patients with relapsed/refractory or high-risk leukemias enrolled on a prospective clinical trial conducted by the LEAP Consortium. Eighteen percent of patients had a high confidence Tier 1 or 2 recommendation. We describe clinical responses in the 14% of patients with relapsed/refractory leukemia who received the matched targeted therapy. Further, in order to inform future targeted therapy for patients, we validated variants of uncertain sig-nificance, performed ex vivo drug-sensitivity testing in patient leukemia samples, and identified new combinations of targeted therapies in cell lines and patient-derived xenograft models. These data and our collaborative approach should inform the design of future precision medicine trials. Significance: Patients with relapsed/refractory leukemias face limited treatment options. System-atic integration of precision medicine efforts can inform therapy. We report the feasibility of identify-ing targetable mutations in children with leukemia and describe correlative biology studies validating therapeutic hypotheses and novel mutations. © 2021 American Association for Cancer Research. |
| Journal Title: | Cancer Discovery |
| Volume: | 11 |
| Issue: | 6 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-06-01 |
| Start Page: | 1424 |
| End Page: | 1439 |
| Language: | English |
| DOI: | 10.1158/2159-8290.Cd-20-0564 |
| PUBMED: | 33563661 |
| PROVIDER: | scopus |
| PMCID: | PMC8178162 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work